ImmuPharma plc, a drug discovery and development company focusing on the treatment of serious medical conditions such as Lupus, cancer pain and MRSA, is seeking admission to AIM. ImmuPharma is developing drug candidates which seek to address pressing unmet medical needs and are expected to have significant sales potential and high margins.
